Nuo Therapeutics Inc (NUOT) 0.1300 $NUOT
Nuo Therapeutics Announces Execution of Limited Consent With Deerfield Management Through December 4, 2015
GlobeNewswire - Thu Nov 12, 7:24PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the execution as of November 11, 2015 of a limited consent with Deerfield Management, L.P. and certain of its affiliates pursuant to which the Deerfield Facility Agreement was modified to provide that:
Nuo Therapeutics Announces 3rd Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 7:24PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today reported financial results for the third quarter ended September 30, 2015 and provided a strategic and operational update.
Nuo Therapeutics to Hold Third Quarter 2015 Conference Call on Friday, November 13 at 8:00 a.m. Eastern Time
GlobeNewswire - Wed Nov 04, 7:30AM CST
Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of market.
Nuo Therapeutics Responds to Favorable CMS Hospital Outpatient Payment Final Ruling for Aurix System
GlobeNewswire - Mon Nov 02, 7:31AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the Aurix(TM) System reimbursement rate under the Hospital Outpatient Prospective Payment System (HOPPS) for the calendar year 2016 has been published by the Centers for Medicare and Medicaid Services (CMS). Aurix was placed in Ambulatory Payment Classification (APC) 5054 (Level 4 Skin Procedures) and will be reimbursed at a national average rate of $1,411 per application effective January 1, 2016. In the text of the ruling, CMS commented they believe the geometric mean cost of the services underlying Aurix is comparable to the geometric mean cost of APC 5054.
Nuo Therapeutics Executes Amended Licensing Agreement With Arthrex
GlobeNewswire - Tue Oct 20, 7:30AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced it has executed an amended and restated license agreement with Arthrex, Inc., through which Arthrex has exercised its right to assume responsibility for the manufacture and supply of the Company's Angel(R) Concentrated Platelet Rich Plasma System (Angel), an option granted and contemplated in the original license agreement. Additionally, Nuo is retaining the underlying patents to Angel while transferring the as-defined product registration rights and obligations.
Global Intermittent Claudication Pipeline Review 2015 - 6 Companies & 6 Drug Profiles
M2 - Mon Oct 05, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/678332/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Intermittent Claudication, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Intermittent Claudication and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cytokinetics, Inc. - DNAVEC Corporation - Kowa Company, Ltd. - LTT Bio-Pharma Co., Ltd. - Nuo Therapeutics, Inc. - Pluristem Therapeutics Inc. Drug Profiles - ALD-301 - DVC1-0101 - K-134 - LT-0101 - PLX-PAD - tirasemtiv For more information visit http://www.researchandmarkets.com/research/67...termittent
CYTK: 10.92 (+0.16), PSTI: 1.53 (+0.02)
Global Stem Cell Umbilical Cord Blood Market 2015-2019
M2 - Thu Sep 24, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5r9dpb/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood Market 2015-2019" report to their offering. Public awareness of stem cell UCB banking is increasing due to the various awareness programs conducted. This is done with the motive of making people aware of the potential benefits of cord blood banking. It will result in social and economic benefits as well. At the events, the idea is to educate people about the importance of cord blood banking. This is vital because it can help in the improvement of the quality of life of many patients suffering from life-threatening diseases. Companies such as Americord and Viacord are promoting July as National Stem Cell Awareness month. Similarly, Precious Cells surveyed 1,000 families in UK with children under the age of 10, as part of the National Stem Cell Awareness Day on October 8, 2014. To increase the awareness of cord blood banking, Save the Cord Foundation is partnering with Bioinformant. Also, LifeCell is creating awareness among in India about the need for umbilical cord stem cell banking. These programs help in promoting awareness for present and future stem cell treatments. According to the report, UCB stem cells prove to be an effective treatment option for more than 80 diseases, such as cancer, immunodeficiency disorders, and blood disorders. Many of these diseases, which have no cure, can be treated effectively with the use of stem cells obtained from the umbilical cord. These stem cells travel to the site of damage and identify the defective cells. They then initiate a healing process and are thus used in the treatment. Since they are derived from the same individual, the risk of rejection can also be eliminated. Research is being carried out for the development of UCB stem cells as an effective treatment option for diseases such as diabetes, Alzheimer's disease, brain tumor, and heart failure. They can thus be used as a successful mode of treatment for many of life-threatening diseases. Key Topics Covered - Executive Summary - Introduction - Process of Collection, Processing, and Storage of Cord Blood Cells - Facts: Cord Blood Units - US FDA Approved Stem Cell UCB Product - Pipeline Analysis - Market Landscape - Market Segmentation by Application - Market Segmentation by Storage - Harmonization of Biobanking - Market Segmentation by End-user - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Global Stem Cell UCB Market: Key Takeaways - Key Vendor Analysis Companies Mentioned - Athersys - Caladrius Biosciences - Celgene - CHA Bio & Diostech - Cytori Therapeutics - Mesoblast - Nuo Therapeutics - Ocata Therapeutics - Opexa Therapeutics - Osiris Therapeutics - Pluristem Therapeutics - Teva Pharmaceuticals - United Therapeutics For more information visit http://www.researchandmarkets.com/research/5r..._stem_cell
OCAT: 8.46 (unch), OPXA: 3.01 (-0.10), PSTI: 1.53 (+0.02), CYTX: 0.34 (-0.02), UTHR: 147.65 (+1.66), OSIR: 11.00 (-2.98), CLBS: 1.18 (+0.02), CELGZ: 1.10 (unch)
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015
M2 - Wed Sep 23, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mlsnz6/chronic_coronary) has announced the addition of the "Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Human Stem Cells Institute - Lacer, S.A. - Nuo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/ml...c_coronary
Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019 - Key Vendors are AstraZeneca, Bayer, Eli Lilly, Novartis, Pfizer & Sanofi
M2 - Thu Sep 17, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6skk9g/global_ischemic) has announced the addition of the "Global Ischemic Heart Disease (IHD)Drugs Market 2015-2019" report to their offering. The global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019. The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. The market has huge growth opportunities for vendors because of the growing population of individuals with IHD. To capture maximum market shares and expand the focus area, vendors are investing more on R&D. According to the report, the high prevalence of chronic conditions such as hypertension, diabetes, and cholesterol levels are leading to an increase in cardiovascular diseases. The people with diabetes are three to four times more likely to develop CVDs than people without diabetes. Further, the report states that the availability of effective surgical treatments and the use of catheter based interventions pose a challenge to the growth of market. The need for specific therapeutics at the later stages of the disease leads to the increased reliance on stents and surgeries. IHD includes: - Angina pectoris - Myocardial infarction. Key Vendors - AstraZeneca - Bayer - Eli Lilly - Novartis - Pfizer - Sanofi Other Prominent Vendors - Actelion - Amgen - Baxter - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi-Sankyo - Eisai - F.Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Human Stem Cells Institute - Janssen Pharmaceuticals - Juventas Therapeutics - Lacer - Merck - Nuo Therapeutics - Ono Pharmaceutical - Pharmahungary Group - Resverlogix - Takeda Pharmaceutical Company - Taxus Cardium - The Medicines Company - United Therapeutics For more information visit http://www.researchandmarkets.com/research/6s...l_ischemic
GILD: 104.49 (+0.68), UTHR: 147.65 (+1.66), MRK: 53.78 (+0.08), AMGN: 157.99 (+3.49), LLY: 81.26 (+0.03), GSK: 40.61 (+0.38), BMY: 65.70 (+0.68), NVS: 87.54 (+0.49)
Nuo Therapeutics Launches Educational Program to Support Wound Care Centers in Transition to ICD-10
GlobeNewswire - Mon Sep 14, 7:30AM CDT
First Webinar for Wound Care Professionals to be held September 15 at 1:00 p.m. Eastern on http://www.woundsresearch.com/ICD10
Global Malignant Glioma Pipeline Review 2015
M2 - Tue Sep 08, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ms2wz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Amgen Inc. - AstraZeneca Plc - BBB Therapeutics B.V. - Eisai Co., Ltd. - Eli Lilly and Company - Genmab A/S - Lipopharma Therapeutics SL - MediGene AG - Nuo Therapeutics, Inc. - Pfizer Inc. - Stemline Therapeutics, Inc. - Tiziana Life Sciences Plc - Vicus Therapeutics, LLC - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/5m...ant_glioma
ZIOP: 12.78 (unch), PFE: 33.06 (-0.10), AZN: 33.36 (+0.58), AMGN: 157.99 (+3.49), LLY: 81.26 (+0.03), STML: 8.62 (+0.04)
Nuo Therapeutics Reports Second Quarter 2015 Results and Operational Update
GlobeNewswire - Thu Aug 13, 4:00PM CDT
Adopts Strategic Realignment Plan With Increased Commercial Focus on VA Sales
NUO Therapeutics to Hold Second Quarter 2015 Conference Call on Friday, August 14 at 8:00 a.m. Eastern Time
GlobeNewswire - Wed Aug 12, 8:28AM CDT
NUO Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the second quarter of 2015 on Thursday, August 13, 2015, after the close of market.
WoundExpert(R) Integrates Electronic Data Collection and Reporting for Nuo Therapeutics' Aurix(TM) CED Program
GlobeNewswire - Thu Jul 30, 7:38AM CDT
Net Health, the leader in software solutions for specialized outpatient care, has developed functionality within its WoundExpert(R) software that will provide WoundExpert clients the opportunity to participate in Nuo Therapeutics' Coverage with Evidence Development program (CED) with the Centers for Medicare and Medicaid Services for its Aurix platelet and plasma therapy system. Effective August 17, WoundExpert clients that choose to participate in the Aurix CED program will be able to identify patients that may qualify for participation in the CED, track the necessary data points for those enrolled patients, and produce the required documentation for Medicare reimbursement.
Nuo Therapeutics' Au Study Goes Digital
GlobeNewswire - Thu Jul 30, 7:30AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that its previously reported collaboration with Net Health to add data collection functionality within WoundExpert(R) for the Aurix(TM) Coverage with Evidence Development (CED) program (Au Study) will go live in August.
Nuo Therapeutics and American Academy of Professional Coders Partner to Create First-Ever Wound Care Education Series
GlobeNewswire - Thu Jul 23, 7:30AM CDT
The American Academy of Professional Coders (AAPC) and Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced a multi-year partnership that will elevate the business of healthcare through the creation of educational materials to promote best practices in wound care treatment and business.
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics Pipeline Report 2015 - 22 Companies & 30 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63tfvw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - KunWha Pharmaceutical Co., Ltd. - MedImmune, LLC - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - RegenoCELL Therapeutics, Inc. - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. Drug Profiles - (cilostazol organic nitrate) ER - AEM-28 - ALD-301 - Annexin A-5 - CVBT-141C - DVC1-0101 - ELS-140 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - MEDI-6012 - Mesenchymal Stem Cells - MGN-6114 - MultiGeneAngio - MultiGeneGraft - MultiStem - O-304 - PDA-002 - REC-03 - rivaroxaban - RVX-208 - sarpogrelate SR - selegiline Antiplatelet Drugs - sodium nitrite SR - Stem Cell Therapy for Cardiovascular Diseases - SYN-20112312RU - ticagrelor - transcrocetinate sodium - TXA-127 - VM-202 - vonapanitase For more information visit http://www.researchandmarkets.com/research/63tfvw/peripheral
AZN: 33.36 (+0.58), ATHX: 1.01 (-0.01), PRTO: 14.42 (-0.54), CELGZ: 1.10 (unch)
Global Stem Cell Therapy Market Future Outlook
M2 - Tue Jul 07, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vdbl4h/global_stem_cell) has announced the addition of the "Global Stem Cell Therapy Market Future Outlook" report to their offering. As per recent research report "Global Stem Cell Therapy Market Future Outlook", advancement in stem cell research seems to be increasing continuously across the globe which is apparent from the number of increasing clinical trials. Stem cell therapies for numerous indications are at different stages of clinical trials and they would be introduced in market in coming years. Increased findings and quest for better therapeutics could be considered as main reason behind growth of this segment. Improved technology and development of innovative modalities are further expected to propel the development of stem cell therapies. Only few stem cell therapies have received approval and most of them are small part of forth coming medical revolution. Stem cell therapy developers would be able to generate significant revenues in coming years. In this way, future prospects of stem cell therapies look optimistic and it is expected that more stem cell therapies would be commercialized in coming years. "Global Stem Cell Therapy Market Future Outlook" Report Highlight: - Global Stem Cell Market Analysis - Trends in Stem Cell Research - Global Stem Cell Market Dynamics: Favorable Factors & Commercialization Challenges - Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase - Global Stem Cell Therapies in Clinical Pipeline: 114 Therapies - Majority Stem Cell Therapies in Preclinical Phase: 38 Therapies - Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication - Marketed Stem Cell Therapies Clinical: 2 Therapies (Adipocell? & VesCell) Key Topics Covered: 1. Introduction to Stem Cells 2. Classification of Stem Cells 3. Different Type of Stem Cell Transplants 4. Mechanism of Stem Cell Therapy 5. Trends in Stem Cell Research 6. Global Stem Cell Market Analysis 7. Global Stem Cell Market Dynamics 8. Stem Cell Market Future Prospects 9. Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase 10. Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication 11. Discontinued & Suspended Stem Cell Therapies in Clinical Pipeline 12. Competitive Landscape - Aldagen - AlloCure - Anterogen - Arteriocyte Medical Systems - Athersys - Baxter Healthcare Corporation - Bioheart - Caladrius - Cambridge Enterprise - Celgene Corporation - CellPraxis - Cellerant Therapeutics - Cryopraxis - Cytori Therapeutics - Gamida Cell - Genexine - Geron - Intrexon Corporation - K-STEMCELL - Lifecells - Novartis - Nuo Therapeutics - Ocata Therapeutics - OmniCyte - OncoMed - Osiris Therapeutics - Pharmicell - Pluristem Therapeutics - Promethera Biosciences - ReNeuron - Stem Cell Sciences - Stemedica Cell Technologies - TCA Cellular Therapy - TiGenix - Vericel Corporation For more information visit http://www.researchandmarkets.com/research/vd..._stem_cell
OCAT: 8.46 (unch), VCEL: 1.72 (-0.05), PSTI: 1.53 (+0.02), CYTX: 0.34 (-0.02), OSIR: 11.00 (-2.98), MDSY: 2.17 (+0.12), XON: 35.29 (+0.35), NVS: 87.54 (+0.49), CELGZ: 1.10 (unch)
Nuo Therapeutics to Support 35th Annual National Veterans Wheelchair Games
GlobeNewswire - Wed Jun 17, 7:30AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced its participation in the 35 Annual National Veterans Wheelchair Games (NVWG), presented by the Department of Veterans Affairs (VA) and Paralyzed Veterans of America (PVA), taking place June 21 - 26 in Dallas, TX.
Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kl4nwn/peripheral_artery) has announced the addition of the "Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Annexin Pharmaceuticals AB - Apceth GmbH & Co. KG - AstraZeneca PLC - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Cytokinetics, Inc. - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Genovate Biotechnology Co., LTD. - Grifols, S.A. - Human Stem Cells Institute - Kowa Company, Ltd. - Lacer, S.A. - Ligand Pharmaceuticals, Inc. - LTT Bio-Pharma Co., Ltd. - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Pluristem Therapeutics Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - RegenoCELL Therapeutics, Inc. - Rigel Pharmaceuticals, Inc. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Taisho Toyama Pharmaceutical Co., Ltd. - Theravasc, Inc. - vasopharm GmbH - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/kl...ral_artery
CYTK: 10.92 (+0.16), PSTI: 1.53 (+0.02), RIGL: 2.92 (-0.08), PRTO: 14.42 (-0.54), AZN: 33.36 (+0.58), ATHX: 1.01 (-0.01), CELGZ: 1.10 (unch)
Nuo Therapeutics Announces Execution of Limited Consent With Deerfield Management Through December 4, 2015
GlobeNewswire - Thu Nov 12, 7:24PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the execution as of November 11, 2015 of a limited consent with Deerfield Management, L.P. and certain of its affiliates pursuant to which the Deerfield Facility Agreement was modified to provide that:
Nuo Therapeutics Announces 3rd Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 7:24PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today reported financial results for the third quarter ended September 30, 2015 and provided a strategic and operational update.
Nuo Therapeutics to Hold Third Quarter 2015 Conference Call on Friday, November 13 at 8:00 a.m. Eastern Time
GlobeNewswire - Wed Nov 04, 7:30AM CST
Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of market.
Nuo Therapeutics Responds to Favorable CMS Hospital Outpatient Payment Final Ruling for Aurix System
GlobeNewswire - Mon Nov 02, 7:31AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the Aurix(TM) System reimbursement rate under the Hospital Outpatient Prospective Payment System (HOPPS) for the calendar year 2016 has been published by the Centers for Medicare and Medicaid Services (CMS). Aurix was placed in Ambulatory Payment Classification (APC) 5054 (Level 4 Skin Procedures) and will be reimbursed at a national average rate of $1,411 per application effective January 1, 2016. In the text of the ruling, CMS commented they believe the geometric mean cost of the services underlying Aurix is comparable to the geometric mean cost of APC 5054.
Nuo Therapeutics Executes Amended Licensing Agreement With Arthrex
GlobeNewswire - Tue Oct 20, 7:30AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced it has executed an amended and restated license agreement with Arthrex, Inc., through which Arthrex has exercised its right to assume responsibility for the manufacture and supply of the Company's Angel(R) Concentrated Platelet Rich Plasma System (Angel), an option granted and contemplated in the original license agreement. Additionally, Nuo is retaining the underlying patents to Angel while transferring the as-defined product registration rights and obligations.
Global Intermittent Claudication Pipeline Review 2015 - 6 Companies & 6 Drug Profiles
M2 - Mon Oct 05, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/678332/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Intermittent Claudication, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Intermittent Claudication and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cytokinetics, Inc. - DNAVEC Corporation - Kowa Company, Ltd. - LTT Bio-Pharma Co., Ltd. - Nuo Therapeutics, Inc. - Pluristem Therapeutics Inc. Drug Profiles - ALD-301 - DVC1-0101 - K-134 - LT-0101 - PLX-PAD - tirasemtiv For more information visit http://www.researchandmarkets.com/research/67...termittent
CYTK: 10.92 (+0.16), PSTI: 1.53 (+0.02)
Global Stem Cell Umbilical Cord Blood Market 2015-2019
M2 - Thu Sep 24, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5r9dpb/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood Market 2015-2019" report to their offering. Public awareness of stem cell UCB banking is increasing due to the various awareness programs conducted. This is done with the motive of making people aware of the potential benefits of cord blood banking. It will result in social and economic benefits as well. At the events, the idea is to educate people about the importance of cord blood banking. This is vital because it can help in the improvement of the quality of life of many patients suffering from life-threatening diseases. Companies such as Americord and Viacord are promoting July as National Stem Cell Awareness month. Similarly, Precious Cells surveyed 1,000 families in UK with children under the age of 10, as part of the National Stem Cell Awareness Day on October 8, 2014. To increase the awareness of cord blood banking, Save the Cord Foundation is partnering with Bioinformant. Also, LifeCell is creating awareness among in India about the need for umbilical cord stem cell banking. These programs help in promoting awareness for present and future stem cell treatments. According to the report, UCB stem cells prove to be an effective treatment option for more than 80 diseases, such as cancer, immunodeficiency disorders, and blood disorders. Many of these diseases, which have no cure, can be treated effectively with the use of stem cells obtained from the umbilical cord. These stem cells travel to the site of damage and identify the defective cells. They then initiate a healing process and are thus used in the treatment. Since they are derived from the same individual, the risk of rejection can also be eliminated. Research is being carried out for the development of UCB stem cells as an effective treatment option for diseases such as diabetes, Alzheimer's disease, brain tumor, and heart failure. They can thus be used as a successful mode of treatment for many of life-threatening diseases. Key Topics Covered - Executive Summary - Introduction - Process of Collection, Processing, and Storage of Cord Blood Cells - Facts: Cord Blood Units - US FDA Approved Stem Cell UCB Product - Pipeline Analysis - Market Landscape - Market Segmentation by Application - Market Segmentation by Storage - Harmonization of Biobanking - Market Segmentation by End-user - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Global Stem Cell UCB Market: Key Takeaways - Key Vendor Analysis Companies Mentioned - Athersys - Caladrius Biosciences - Celgene - CHA Bio & Diostech - Cytori Therapeutics - Mesoblast - Nuo Therapeutics - Ocata Therapeutics - Opexa Therapeutics - Osiris Therapeutics - Pluristem Therapeutics - Teva Pharmaceuticals - United Therapeutics For more information visit http://www.researchandmarkets.com/research/5r..._stem_cell
OCAT: 8.46 (unch), OPXA: 3.01 (-0.10), PSTI: 1.53 (+0.02), CYTX: 0.34 (-0.02), UTHR: 147.65 (+1.66), OSIR: 11.00 (-2.98), CLBS: 1.18 (+0.02), CELGZ: 1.10 (unch)
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015
M2 - Wed Sep 23, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mlsnz6/chronic_coronary) has announced the addition of the "Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Human Stem Cells Institute - Lacer, S.A. - Nuo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/ml...c_coronary
Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019 - Key Vendors are AstraZeneca, Bayer, Eli Lilly, Novartis, Pfizer & Sanofi
M2 - Thu Sep 17, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6skk9g/global_ischemic) has announced the addition of the "Global Ischemic Heart Disease (IHD)Drugs Market 2015-2019" report to their offering. The global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019. The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. The market has huge growth opportunities for vendors because of the growing population of individuals with IHD. To capture maximum market shares and expand the focus area, vendors are investing more on R&D. According to the report, the high prevalence of chronic conditions such as hypertension, diabetes, and cholesterol levels are leading to an increase in cardiovascular diseases. The people with diabetes are three to four times more likely to develop CVDs than people without diabetes. Further, the report states that the availability of effective surgical treatments and the use of catheter based interventions pose a challenge to the growth of market. The need for specific therapeutics at the later stages of the disease leads to the increased reliance on stents and surgeries. IHD includes: - Angina pectoris - Myocardial infarction. Key Vendors - AstraZeneca - Bayer - Eli Lilly - Novartis - Pfizer - Sanofi Other Prominent Vendors - Actelion - Amgen - Baxter - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi-Sankyo - Eisai - F.Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Human Stem Cells Institute - Janssen Pharmaceuticals - Juventas Therapeutics - Lacer - Merck - Nuo Therapeutics - Ono Pharmaceutical - Pharmahungary Group - Resverlogix - Takeda Pharmaceutical Company - Taxus Cardium - The Medicines Company - United Therapeutics For more information visit http://www.researchandmarkets.com/research/6s...l_ischemic
GILD: 104.49 (+0.68), UTHR: 147.65 (+1.66), MRK: 53.78 (+0.08), AMGN: 157.99 (+3.49), LLY: 81.26 (+0.03), GSK: 40.61 (+0.38), BMY: 65.70 (+0.68), NVS: 87.54 (+0.49)
Nuo Therapeutics Launches Educational Program to Support Wound Care Centers in Transition to ICD-10
GlobeNewswire - Mon Sep 14, 7:30AM CDT
First Webinar for Wound Care Professionals to be held September 15 at 1:00 p.m. Eastern on http://www.woundsresearch.com/ICD10
Global Malignant Glioma Pipeline Review 2015
M2 - Tue Sep 08, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ms2wz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Amgen Inc. - AstraZeneca Plc - BBB Therapeutics B.V. - Eisai Co., Ltd. - Eli Lilly and Company - Genmab A/S - Lipopharma Therapeutics SL - MediGene AG - Nuo Therapeutics, Inc. - Pfizer Inc. - Stemline Therapeutics, Inc. - Tiziana Life Sciences Plc - Vicus Therapeutics, LLC - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/5m...ant_glioma
ZIOP: 12.78 (unch), PFE: 33.06 (-0.10), AZN: 33.36 (+0.58), AMGN: 157.99 (+3.49), LLY: 81.26 (+0.03), STML: 8.62 (+0.04)
Nuo Therapeutics Reports Second Quarter 2015 Results and Operational Update
GlobeNewswire - Thu Aug 13, 4:00PM CDT
Adopts Strategic Realignment Plan With Increased Commercial Focus on VA Sales
NUO Therapeutics to Hold Second Quarter 2015 Conference Call on Friday, August 14 at 8:00 a.m. Eastern Time
GlobeNewswire - Wed Aug 12, 8:28AM CDT
NUO Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the second quarter of 2015 on Thursday, August 13, 2015, after the close of market.
WoundExpert(R) Integrates Electronic Data Collection and Reporting for Nuo Therapeutics' Aurix(TM) CED Program
GlobeNewswire - Thu Jul 30, 7:38AM CDT
Net Health, the leader in software solutions for specialized outpatient care, has developed functionality within its WoundExpert(R) software that will provide WoundExpert clients the opportunity to participate in Nuo Therapeutics' Coverage with Evidence Development program (CED) with the Centers for Medicare and Medicaid Services for its Aurix platelet and plasma therapy system. Effective August 17, WoundExpert clients that choose to participate in the Aurix CED program will be able to identify patients that may qualify for participation in the CED, track the necessary data points for those enrolled patients, and produce the required documentation for Medicare reimbursement.
Nuo Therapeutics' Au Study Goes Digital
GlobeNewswire - Thu Jul 30, 7:30AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that its previously reported collaboration with Net Health to add data collection functionality within WoundExpert(R) for the Aurix(TM) Coverage with Evidence Development (CED) program (Au Study) will go live in August.
Nuo Therapeutics and American Academy of Professional Coders Partner to Create First-Ever Wound Care Education Series
GlobeNewswire - Thu Jul 23, 7:30AM CDT
The American Academy of Professional Coders (AAPC) and Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced a multi-year partnership that will elevate the business of healthcare through the creation of educational materials to promote best practices in wound care treatment and business.
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics Pipeline Report 2015 - 22 Companies & 30 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63tfvw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - KunWha Pharmaceutical Co., Ltd. - MedImmune, LLC - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - RegenoCELL Therapeutics, Inc. - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. Drug Profiles - (cilostazol organic nitrate) ER - AEM-28 - ALD-301 - Annexin A-5 - CVBT-141C - DVC1-0101 - ELS-140 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - MEDI-6012 - Mesenchymal Stem Cells - MGN-6114 - MultiGeneAngio - MultiGeneGraft - MultiStem - O-304 - PDA-002 - REC-03 - rivaroxaban - RVX-208 - sarpogrelate SR - selegiline Antiplatelet Drugs - sodium nitrite SR - Stem Cell Therapy for Cardiovascular Diseases - SYN-20112312RU - ticagrelor - transcrocetinate sodium - TXA-127 - VM-202 - vonapanitase For more information visit http://www.researchandmarkets.com/research/63tfvw/peripheral
AZN: 33.36 (+0.58), ATHX: 1.01 (-0.01), PRTO: 14.42 (-0.54), CELGZ: 1.10 (unch)
Global Stem Cell Therapy Market Future Outlook
M2 - Tue Jul 07, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vdbl4h/global_stem_cell) has announced the addition of the "Global Stem Cell Therapy Market Future Outlook" report to their offering. As per recent research report "Global Stem Cell Therapy Market Future Outlook", advancement in stem cell research seems to be increasing continuously across the globe which is apparent from the number of increasing clinical trials. Stem cell therapies for numerous indications are at different stages of clinical trials and they would be introduced in market in coming years. Increased findings and quest for better therapeutics could be considered as main reason behind growth of this segment. Improved technology and development of innovative modalities are further expected to propel the development of stem cell therapies. Only few stem cell therapies have received approval and most of them are small part of forth coming medical revolution. Stem cell therapy developers would be able to generate significant revenues in coming years. In this way, future prospects of stem cell therapies look optimistic and it is expected that more stem cell therapies would be commercialized in coming years. "Global Stem Cell Therapy Market Future Outlook" Report Highlight: - Global Stem Cell Market Analysis - Trends in Stem Cell Research - Global Stem Cell Market Dynamics: Favorable Factors & Commercialization Challenges - Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase - Global Stem Cell Therapies in Clinical Pipeline: 114 Therapies - Majority Stem Cell Therapies in Preclinical Phase: 38 Therapies - Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication - Marketed Stem Cell Therapies Clinical: 2 Therapies (Adipocell? & VesCell) Key Topics Covered: 1. Introduction to Stem Cells 2. Classification of Stem Cells 3. Different Type of Stem Cell Transplants 4. Mechanism of Stem Cell Therapy 5. Trends in Stem Cell Research 6. Global Stem Cell Market Analysis 7. Global Stem Cell Market Dynamics 8. Stem Cell Market Future Prospects 9. Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase 10. Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication 11. Discontinued & Suspended Stem Cell Therapies in Clinical Pipeline 12. Competitive Landscape - Aldagen - AlloCure - Anterogen - Arteriocyte Medical Systems - Athersys - Baxter Healthcare Corporation - Bioheart - Caladrius - Cambridge Enterprise - Celgene Corporation - CellPraxis - Cellerant Therapeutics - Cryopraxis - Cytori Therapeutics - Gamida Cell - Genexine - Geron - Intrexon Corporation - K-STEMCELL - Lifecells - Novartis - Nuo Therapeutics - Ocata Therapeutics - OmniCyte - OncoMed - Osiris Therapeutics - Pharmicell - Pluristem Therapeutics - Promethera Biosciences - ReNeuron - Stem Cell Sciences - Stemedica Cell Technologies - TCA Cellular Therapy - TiGenix - Vericel Corporation For more information visit http://www.researchandmarkets.com/research/vd..._stem_cell
OCAT: 8.46 (unch), VCEL: 1.72 (-0.05), PSTI: 1.53 (+0.02), CYTX: 0.34 (-0.02), OSIR: 11.00 (-2.98), MDSY: 2.17 (+0.12), XON: 35.29 (+0.35), NVS: 87.54 (+0.49), CELGZ: 1.10 (unch)
Nuo Therapeutics to Support 35th Annual National Veterans Wheelchair Games
GlobeNewswire - Wed Jun 17, 7:30AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced its participation in the 35 Annual National Veterans Wheelchair Games (NVWG), presented by the Department of Veterans Affairs (VA) and Paralyzed Veterans of America (PVA), taking place June 21 - 26 in Dallas, TX.
Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kl4nwn/peripheral_artery) has announced the addition of the "Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Annexin Pharmaceuticals AB - Apceth GmbH & Co. KG - AstraZeneca PLC - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Cytokinetics, Inc. - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Genovate Biotechnology Co., LTD. - Grifols, S.A. - Human Stem Cells Institute - Kowa Company, Ltd. - Lacer, S.A. - Ligand Pharmaceuticals, Inc. - LTT Bio-Pharma Co., Ltd. - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Pluristem Therapeutics Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - RegenoCELL Therapeutics, Inc. - Rigel Pharmaceuticals, Inc. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Taisho Toyama Pharmaceutical Co., Ltd. - Theravasc, Inc. - vasopharm GmbH - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/kl...ral_artery
CYTK: 10.92 (+0.16), PSTI: 1.53 (+0.02), RIGL: 2.92 (-0.08), PRTO: 14.42 (-0.54), AZN: 33.36 (+0.58), ATHX: 1.01 (-0.01), CELGZ: 1.10 (unch)
